Pyridorin: Completed Phase IIb enrollment

NephroGenex completed enrollment of 317 patients in a double-blind, international Phase IIb trial

Read the full 135 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE